Literature DB >> 33758229

Standardization of esophageal adenocarcinoma in vitro model and its applicability for model drug testing.

Larisa Tratnjek1, Nadica Sibinovska2, Slavko Kralj3, Darko Makovec3, Katja Kristan4, Mateja Erdani Kreft5.   

Abstract

FLO-1 cell line represents an important tool in esophageal adenocarcinoma (EAC) research as a verified and authentic cell line to study the disease pathophysiology and antitumor drug screenings. Since in vitro characteristics of cells depend on the microenvironment and culturing conditions, we performed a thorough characterization of the FLO-1 cell line under different culturing conditions with the aim of (1) examining the effect of serum-free growth medium and air-liquid interface (A-L) culturing, which better reflect physiological conditions in vivo and (2) investigating the differentiation potential of FLO-1 cells to mimic the properties of the in vivo esophageal epithelium. Our study shows that the composition of the media influenced the morphological, ultrastructural and molecular characteristics of FLO-1 cells, such as the expression of junctional proteins. Importantly, FLO-1 cells formed spheres at the A-L interface, recapitulating key elements of tumors in the esophageal tube, i.e., direct contact with the gas phase and three-dimensional architecture. On the other hand, FLO-1 models exhibited high permeability to model drugs and zero permeability markers, and low transepithelial resistance, and therefore poorly mimicked normal esophageal epithelium. In conclusion, the identified effect of culture conditions on the characteristics of FLO-1 cells should be considered for standardization, data reproducibility and validity of the in vitro EAC model. Moreover, the sphere-forming ability of FLO-1 cells at the A-L interface should be considered in EAC tumor biology and anticancer drug studies as a reliable and straightforward model with the potential to increase the predictive efficiency of the current in vitro approaches.

Entities:  

Year:  2021        PMID: 33758229     DOI: 10.1038/s41598-021-85530-w

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  86 in total

1.  Esophageal adenocarcinoma incidence: are we reaching the peak?

Authors:  Heiko Pohl; Brenda Sirovich; H Gilbert Welch
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

2.  Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia.

Authors:  W H Chow; W J Blot; T L Vaughan; H A Risch; M D Gammon; J L Stanford; R Dubrow; J B Schoenberg; S T Mayne; D C Farrow; H Ahsan; A B West; H Rotterdam; S Niwa; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1998-01-21       Impact factor: 13.506

Review 3.  Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma.

Authors:  Joel H Rubenstein; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2015-05-07       Impact factor: 22.682

4.  Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.

Authors:  Jurjen J Boonstra; Ronald van Marion; David G Beer; Lin Lin; Paula Chaves; Catarina Ribeiro; A Dias Pereira; Lúcia Roque; S Jane Darnton; Nasser K Altorki; David S Schrump; David S Klimstra; Laura H Tang; James R Eshleman; Hector Alvarez; Yutaka Shimada; Herman van Dekken; Hugo W Tilanus; Winand N M Dinjens
Journal:  J Natl Cancer Inst       Date:  2010-01-14       Impact factor: 13.506

Review 5.  Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities.

Authors:  Kyle J Napier; Mary Scheerer; Subhasis Misra
Journal:  World J Gastrointest Oncol       Date:  2014-05-15

6.  Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus.

Authors:  D C Whiteman; S Sadeghi; N Pandeya; B M Smithers; D C Gotley; C J Bain; P M Webb; A C Green
Journal:  Gut       Date:  2007-10-11       Impact factor: 23.059

7.  Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis.

Authors:  Jamie M J Weaver; Caryn S Ross-Innes; Nicholas Shannon; Andy G Lynch; Tim Forshew; Mariagnese Barbera; Muhammed Murtaza; Chin-Ann J Ong; Pierre Lao-Sirieix; Mark J Dunning; Laura Smith; Mike L Smith; Charlotte L Anderson; Benilton Carvalho; Maria O'Donovan; Timothy J Underwood; Andrew P May; Nicola Grehan; Richard Hardwick; Jim Davies; Arusha Oloumi; Sam Aparicio; Carlos Caldas; Matthew D Eldridge; Paul A W Edwards; Nitzan Rosenfeld; Simon Tavaré; Rebecca C Fitzgerald
Journal:  Nat Genet       Date:  2014-06-22       Impact factor: 38.330

Review 8.  In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform.

Authors:  Moriah E Katt; Amanda L Placone; Andrew D Wong; Zinnia S Xu; Peter C Searson
Journal:  Front Bioeng Biotechnol       Date:  2016-02-12

9.  Whole-genome sequencing of nine esophageal adenocarcinoma cell lines.

Authors:  Gianmarco Contino; Matthew D Eldridge; Maria Secrier; Lawrence Bower; Rachael Fels Elliott; Jamie Weaver; Andy G Lynch; Paul A W Edwards; Rebecca C Fitzgerald
Journal:  F1000Res       Date:  2016-06-10

10.  Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.

Authors:  Austin M Dulak; Petar Stojanov; Shouyong Peng; Michael S Lawrence; Cameron Fox; Chip Stewart; Santhoshi Bandla; Yu Imamura; Steven E Schumacher; Erica Shefler; Aaron McKenna; Scott L Carter; Kristian Cibulskis; Andrey Sivachenko; Gordon Saksena; Douglas Voet; Alex H Ramos; Daniel Auclair; Kristin Thompson; Carrie Sougnez; Robert C Onofrio; Candace Guiducci; Rameen Beroukhim; Zhongren Zhou; Lin Lin; Jules Lin; Rishindra Reddy; Andrew Chang; Rodney Landrenau; Arjun Pennathur; Shuji Ogino; James D Luketich; Todd R Golub; Stacey B Gabriel; Eric S Lander; David G Beer; Tony E Godfrey; Gad Getz; Adam J Bass
Journal:  Nat Genet       Date:  2013-03-24       Impact factor: 38.330

View more
  1 in total

1.  Barrett's Metaplasia Progression towards Esophageal Adenocarcinoma: An Attempt to Select a Panel of Molecular Sensors and to Reflect Clinical Alterations by Experimental Models.

Authors:  Edyta Korbut; Kinga Krukowska; Marcin Magierowski
Journal:  Int J Mol Sci       Date:  2022-03-18       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.